Jane V. Aldrich, Ph.D.

Jane Aldrich

Contact Information

Dr. Jane V. Aldrich
Department of Medicinal Chemistry
University of Florida College of Pharmacy
P.O. Box 100485
Gainesville, FL 32610-0485
Phone: (352) 273-8708
FAX: (352) 392-9455
E-mail: janealdrich@ufl.edu
Website: Department of Medicinal Chemistry Profile

Position

Professor, Department of Medicinal Chemistry, University of Florida College of Pharmacy

Research Area

The medicinal chemistry of opioid peptides.

Training

B.S., Michigan State University, Department of Biochemistry
Ph.D., University of Michigan, Interdepartmental Program in Medicinal Chemistry. Thesis Advisor: Dr. Raymond E. Counsell.
Postdoctoral Fellowship, University of Minnesota, Medicinal Chemistry. Advisor: Dr. Philip S. Portoghese.

Current Research

Dr. Aldrich’s research focuses on the medicinal chemistry of opioid peptides and involves the design, synthesis and evaluation of peptide and peptidomimetic ligands for opioid receptors, particularly ligands for kappa opioid receptors. Her recent research has focused on novel macrocyclic tetrapeptides with opioid activity that are active in the brain after oral administration. As part of this research, her lab is exploring how structure affects the distribution of the compounds, including their ability to cross biological barriers, and examining metabolism to guide the preparation of additional analogs. They are also performing in vivo pharmacokinetic analysis of key compounds in the series.

Recent Publications

    • Wei-Jie Fang, Thomas F. Murray, and Jane V. Aldrich, “Design, synthesis, and opioid activity of arodyn analogs cyclized by ring-closing metathesis involving Tyr(Allyl),” Bioorg. Med. Chem., in press.
    • Anand A. Joshi, Thomas F. Murray, and Jane V. Aldrich, “Alanine scan of the opioid peptide dynorphin B amide,” Biopolymers (Peptide Science), 2017, in press, doi: 10.1002/bip.23026.
    • Archana Mukhopadhyay, Laura Hanold, Solomon Gisemba, Sanjeewa Senadheera, and Jane V. Aldrich, “Macrocyclic peptides decrease cMyc protein levels and reduce prostate cancer cell growth,” Cancer Biol. Ther. 2017, 18, 571-583.
    • Jane V. Aldrich, “Peptide Lead Optimization – Strategies and Tactics “ in Peptide-Based Drug Discovery: Challenges and Opportunities, Ved Srivastava, Ed. Royal Society of Chemistry, London, 2017, pp 192-222.
    • Tanvir Khaliq, Todd D. Williams, Sanjeewa N. Senadheera and Jane V. Aldrich, “Development of a robust, sensitive and selective liquid chromatography-tandem mass spectrometry assay for the quantification of the novel macrocyclic peptide kappa opioid receptor antagonist [D-Trp]CJ-15,208 in plasma and application to an initial pharmacokinetic study,” J. Chromatogr. B 2016, 1028, 11–15; DOI:10.1016/j.jchromb.2016.05.043.
    • Peng Huang, Tatyana Yakovleva, Jane V Aldrich, and Lee-Yuan Liu-Chen, Zyklophin and Norbinaltorphimine, Two Short-acting Kappa Opioid Receptor Antagonists (Ayklophin and LY244296) Exhibited Different Behavioral Effects from the Long-acting Antagonist Norbinaltorphimine in Mouse Anxiety Tests, Neurosci. Lett. 2016, 615, 15-20; DOI: 10.1016/j.neulet.2016.01.017.
    • Sunil Sirohi, Jane V. Aldrich, and Brendan M. Walker, “Species Differences in the Effects of the K-Opioid Receptor Antagonist Zyklophin,” Alcohol 2016, 51, 43-49; DOI: 10.1016/j.alcohol.2015.11.012
    • Anand A. Joshi, Thomas F. Murray, and Jane V. Aldrich, “Structure-Activity Relationships of the Peptide Kappa Opioid Receptor Antagonist Zyklophin,” J. Med. Chem. 2015, 58, 8783-8795; DOI: 10.1021/jm501827k.
    • Michael J. Ferracane and Jane V. Aldrich, “Opioid Ligand Binding to Opioid Receptors: Insight and Implications for Peptide Design,” Peptides 2015; Proceedings of the 24th American Peptide Symposium, Ved Srivastava, Andrei Yudin and Michal Lebl, Eds., American Peptide Society, 2015, pp 22-23; DOI: 10.17952/24APS.2015.022.
    • Sanjeewa N. Senadheera and Jane V. Aldrich, “Optimized Method to Generate Synthetically Challenging Macrocyclic Tetrapeptides That Do Not Have a Turn Inducer,” Peptides 2015; Proceedings of the 24th American Peptide Symposium, Ved Srivastava, Andrei Yudin and Michal Lebl, Eds., American Peptide Society, 2015, pp 125-126; DOI: 10.17952/24APS.2015.125.
    • Solomon Gisemba and Jane V. Aldrich, Peptide Ring Closing Metathesis: Minimizing Side Reactions in Arodyn Analogs,” Peptides 2015; Proceedings of the 24th American Peptide Symposium, Ved Srivastava, Andrei Yudin and Michal Lebl, Eds., American Peptide Society, 2015, pp 177-178; DOI: 10.17952/24APS.2015.177.
    • Tatyana Yakovleva and Jane V. Aldrich, “Optimizing a Larger Scale Synthesis of Zyklophin, a Highly Selective Peptide Kappa Opioid Receptor Antagonist,” Proceedings of the 24th American Peptide Symposium, Ved Srivastava, Andrei Yudin and Michal Lebl, Eds., American Peptide Society, 2015, pp 283-285; DOI: 10.17952/24APS.2015.283.
    • J. V. Aldrich, S. N. Senadheera, N. C. Ross, K.A. Reilley, M. L. Ganno, S. E. Eans, T. F. Murray, and J. P. McLaughlin, “Alanine Analogs of [D-Trp]CJ-15,208: Novel Opioid Activity Profiles and Prevention of Drug- and Stress-Induced Reinstatement of CocaineSeeking Behavior,” Br. J. Pharmacol. 2014, 171, 3212-3222.
    • K. M. DiMattio, T. V. Yakovleva, J. V. Aldrich, A. Cowan and L. Y. Liu-Chen, “Zyklophin, a short-acting kappa opioid antagonist, induces scratching in mice,” Neuroscience Lett. 2014, 563C, 155-159.
    • Archana Mukhopadhyay, Kayann Tabanor, Rathnam Chaguturu and Jane V. Aldrich, “Targeting Inhibitor of Protein Phosphatase 2A as a Therapeutic Strategy for Prostate Cancer Treatment,” Cancer Biol. Ther. 2013, 14, 962-972.
    • Shainnel O. Eans, Michelle L. Ganno, Kate J. Reilley, Kshitij A. Patkar, Sanjeewa N.Senadheera, Jane V. Aldrich and Jay P. McLaughlin, “The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short acting K opioid receptor antagonism in the CNS after oral administration,” Br. J. Pharmacol. 2013, 169, 426-436.